Skip to main content Accessibility help
×
Home

Prescribing in pregnancy

  • Carol Paton (a1)

Summary

Psychotropic drugs reduce morbidity and mortality related to maternal mental illness but may also cause harm to the foetus, the nature and magnitude of which is not completely understood. Up-to-date information should be shared as fully as possible with the pregnant woman and a treatment plan agreed jointly.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Prescribing in pregnancy
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Prescribing in pregnancy
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Prescribing in pregnancy
      Available formats
      ×

Copyright

References

Hide All
1 Nelson, K, Holmes, LB. Malformations due to presumed mutations in new born infants. N Engl J Med 1989; 320: 1923.
2 Headley, J, Northstone, K, Simmons, H, Golding, J, and the ALSPAC study team. Medication use during pregnancy: data from the Avon longitudinal study of parents and children. Eur J Clin Pharmacol 2004; 60: 355–61.
3 Omtzigt, J. Prenatal diagnosis of spina bifida aperta after first trimester valproate exposure. Prenatal Diagn 1992; 12: 893–7.
4 National Institute for Health and Clinical Excellence. Antenatal and Postnatal Mental Health. Clinical Guideline 45 (http://www.nice.org.uk/nicemedia/pdf/CG045NICEGuidelineCorrected.pdf). NICE, 2007.
5 James, L, Barnes, TRE, Lelliott, P, Taylor, D, Paton, C. Informing patients of the teratogenic potential of mood stabilizing drugs: a case note review of the practice of psychiatrists. J Psychopharmacol 2007; 21: 815–9.
6 Newham, JJ, Thomas, SH, MacRitchie, K, McElhatton, PR, McAlliser-Williams, RH. Birth weight of infants after maternal exposure to typical and atypical antipsychotics. A prospective comparison study. Br J Psychiatry 2008; 192: 333–7.
7 Allison, DB, Mentore, JL, Heo, M, Chandler, LP, Cappelleri, JC, Infante, MC, Weiden, PJ. Antipsychotic-induced weigh gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–96.
8 Ebenbichler, CF, Laimer, M, Eder, U, Mangweth, B, Weiss, E, Hofer, A, Hummer, M, Kemmler, G, Lechleitner, M, Patsch, JR, Fleischhacker, WW. Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry 2003; 64: 1436–9.
9 Diav-Citrin, O, Schechtman, S, Weinbaum, D, Arnon, J, Di Gianantonio, E, Clementi, C, Ornoy, A. Paroxetine and fluoxetine in pregnancy: a multicentre, prospective, controlled study. Reprod Toxicol 2005; 20: 459.
10 Alwan, S, Reefhuis, J, Rasmussen, SA, Olney, RS, Friedman, JM. Use of selective serotonin re-uptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007; 356: 2684–92.
11 Louik, C, Lin, AE, Werler, MM, Hernandez-Diaz, S, Mitchell, AA. First-trimester use of selective serotonin reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356: 2675–83.
12 Ramos, E, At-Andre, M, Roy, E, Oraichi, D, Berand, A. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br J Psychiatry 2008; 192: 344–50.
13 Oberlander, TF, Warburton, W, Misri, S, Aghajanian, J, Hertzman, C. Effects of timing and duration of gestational exposure to selective serotonin reuptake inhibitors: population-based study. Br J Psychiatry 2008; 192: 338–43.
14 McKenna, K, Koren, G, Tetelbaum, M, Wilton, L, Shakir, S, Diav-Citrin, O, Levinson, A, Zipursky, RB, Einarson, A. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005; 66: 444–9.

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Prescribing in pregnancy

  • Carol Paton (a1)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *